Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BUL8

UPID:
PDC10_HUMAN

ALTERNATIVE NAMES:
Cerebral cavernous malformations 3 protein; TF-1 cell apoptosis-related protein 15

ALTERNATIVE UPACC:
Q9BUL8; A8K515; D3DNN5; O14811

BACKGROUND:
The protein Programmed cell death protein 10, with aliases such as TF-1 cell apoptosis-related protein 15, is essential for promoting cell growth, modulating apoptosis, and activating MAP kinase and STK26. It supports KDR/VEGFR2 stability, vital for cardiovascular formation and embryonic blood vessel development.

THERAPEUTIC SIGNIFICANCE:
Given its association with Cerebral cavernous malformations 3, a genetic disorder affecting the central nervous system, Programmed cell death protein 10 offers a promising target for developing treatments for conditions characterized by vascular malformations.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.